Skip to main content
. 2024 Mar 13;24:155. doi: 10.1186/s12872-024-03824-z

Table 1.

Baseline clinical and OCT characteristics

All
(n = 346)
Lower UHR
(n = 173)
Higher UHR
(n = 173)
P value
Age, years 58.83 ± 11.46 61.82 ± 10.71 55.85 ± 11.43 < 0.001
Male, n (%) 266 (76.9) 110 (63.6) 156 (90.2) < 0.001
Medical history, n (%)
 Atrial fibrillation 11 (3.2) 7 (4.0) 4 (2.3) 0.358
 Hypertension 190 (54.9) 94 (54.3) 96 (55.5) 0.829
 Diabetes mellitus 84 (24.3) 40 (23.1) 44 (25.4) 0.616
 CAD 155 (44.8) 78 (45.1) 77 (44.5) 0.914
 Previous PCI 43 (12.4) 19 (11.0) 24 (13.9) 0.415
 Stroke 14 (4.0) 9 (5.2) 5 (2.9) 0.275
Alcohol consumption 54 (15.6) 20 (11.6) 34 (19.7) 0.038
Current smoking 145 (41.9) 53 (30.6) 92 (53.2) < 0.001
 Smoking years 13.74 ± 16.20 10.50 ± 15.64 16.95 ± 16.16 < 0.001
Statins, n (%) 228 (65.9) 107 (61.8) 121 (69.9) 0.112
UA-lowering drugs, n (%) 30 (8.7) 14 (8.1) 16 (9.2) 0.862
 Febuxostat 19 (5.5) 8 (4.6) 11 (6.4)
 Benzbromarone 9 (2.6) 5 (2.9) 4 (2.3)
 Allopurinol 2 (0.6) 1 (0.6) 1 (0.6)
Diagnosis, n (%) 0.103
 Unstable angina 185 (53.5) 101 (58.4) 84 (48.6)
 NSTEMI 110 (31.8) 46 (26.6) 64 (37.0)
 STEMI 51 (14.7) 26 (15.0) 25 (14.5)
Laboratory results, mean ± SD
 WBC, ×109/L 6.98 ± 2.42 6.88 ± 2.62 7.08 ± 2.21 0.459
 Hb, g/L 141.82 ± 17.07 139.323 ± 16.27 144.31 ± 17.52 0.006
 HbA1c, % 6.49 ± 1.69 6.41 ± 1.36 6.56 ± 1.96 0.442
 NT-proBNP, pg/ml 599.78 ± 1756.07 522.21 ± 1439.95 678.76 ± 2029.41 0.414
 Hs-cTnI, pg/ml 316.80 ± 959.76 297.73 ± 921.31 335.52 ± 998.54 0.724
 CK-MB, U/L 25.76 ± 35.76 29.27 ± 43.55 22.33 ± 25.69 0.074
 Glucose, mmol/L 5.99 ± 2.21 5.99 ± 2.53 5.98 ± 1.88 0.961
 Creatine, µmol/L 74.65 ± 50.80 71.90 ± 69.31 77.41 ± 18.93 0.314
 eGFR, ml/min/1.73m2 100.15 ± 25.18 103.37 ± 27.33 96.93 ± 22.44 0.017
 TC, mmol/L 3.79 ± 1.00 3.87 ± 0.94 3.71 ± 1.05 0.148
 TG, mmol/L 1.80 ± 1.43 1.43 ± 0.69 2.17 ± 1.83 < 0.001
 UA, mg/dl 5.47 ± 1.41 4.55 ± 0.95 6.38 ± 1.19 < 0.001
 HDL-C, mg/dl 41.06 ± 10.16 47.37 ± 9.70 34.76 ± 5.76 < 0.001
 UHR (%) 14.36 ± 5.77 9.92 ± 2.37 18.80 ± 4.64 < 0.001
 LDL-C, mmol/L 2.19 ± 0.86 2.24 ± 0.87 2.15 ± 0.86 0.334
 VLDL-C, mmol/L 0.54 ± 0.47 0.42 ± 0.25 0.66 ± 0.60 < 0.001
 Apo A1, g/L 1.24 ± 0.26 1.37 ± 0.26 1.11 ± 0.18 < 0.001
 Apo B, g/L 0.84 ± 0.27 0.83 ± 0.26 0.86 ± 0.27 0.292
 Lp(a), mg/dl 21.90 ± 27.19 25.36 ± 29.83 18.43 ± 23.85 0.018
 TSH, µIU/ml 3.26 ± 4.35 3.89 ± 5.95 2.63 ± 1.42 0.010
 D-dimer, µg/ml 485.62 ± 1098.93 492.01 ± 918.72 479.19 ± 1257.11 0.914
 LVEF, % 63.14 ± 7.94 64.21 ± 7.03 62.06 ± 8.65 0.017
Culprit vessels, n (%) 0.613
 LAD 237 (68.5) 123 (71.1) 114 (65.9)
 LCX 43 (12.4) 20 (11.6) 23 (13.3
 RCA 66 (19.1) 30 (17.3) 36 (20.8)
Lesion site, n (%) 0.220
 Proximal 209 (60.4) 103 (59.5) 106 (61.3)
 Middle 121 (35.0) 65 (37.6) 56 (32.4)
 Distal 16 (4.6) 5 (2.9) 11 (6.4)
Stents, n (%) 0.240
 0 111 (32.1) 61 (35.3) 50 (28.9)
 1 141 (40.8) 72 (41.6) 69 (39.9)
 2 60 (17.3) 29 (16.8) 31 (17.9)
 3 27 (7.8) 9 (5.2) 18 (10.4)
 >3 7 (2.0) 2 (1.2) 5 (2.9)
Plaque morphology, n (%)
 Plaque rupture 95 (27.5) 36 (20.8) 59 (34.1) 0.006
 Plaque erosion 68 (19.7) 26 (15.0) 42 (24.3) 0.054
 Calcified nodule 12 (3.5) 7 (4.0) 5 (2.9) 0.170
Plaque type, n (%)
 Thrombus 118 (34.1) 45 (26.0) 73 (42.2) 0.002
  Red thrombus 6 (1.7) 2 (1.2) 4 (2.3)
  White thrombus 71 (20.5) 30 (17.3) 41 (23.7)
  Mixed thrombus 41 (11.8) 13 (7.5) 28 (16.2)
 TCFA 23 (6.6) 12 (6.9) 11 (6.4) 0.234
 Fibrous plaque 161 (46.5) 79 (45.7) 82 (47.4) 0.441
  FCT of fibrous plaque, µm 981.62 ± 330.96 980.39 ± 362.75 982.83 ± 298.57 0.963
Calcification 89 (25.7) 55 (31.8) 34 (19.7) 0.023
 angle, ° 190.34 ± 112.45 179.23 ± 107.91 206.86 ± 118.51 0.264
 thickness, mm 11.01 ± 93.72 17.62 ± 120.52 0.91 ± 0.29 0.422
 length, mm 23.40 ± 13.11 20.68 ± 9.60 27.27 ± 16.30 0.043
Lipid-rich plaque 88 (25.4) 39 (22.5) 49 (28.3) 0.172
 FCT, µm 147.31 ± 178.09 121.55 ± 88.65 166.75 ± 222.08 0.227
 Lipid arc, ° 204.35 ± 69.60 215.80 ± 60.03 195.54 ± 75.55 0.168
 Cholesterol crystal 151 (43.6) 71 (41.0) 80 (46.2) 0.355
 Micro-vessel 72 (20.8) 33 (19.1) 39 (22.5) 0.265
 Macrophage 87 (25.1) 44 (25.4) 43 (24.9) 0.829
Quantitative of target vessel
 MLA, mm2 2.14 ± 1.37 2.23 ± 1.34 2.03 ± 1.40 0.192
 MLD, mm 1.58 ± 0.46 1.61 ± 0.45 1.55 ± 0.48 0.184
 Diameter stenosis, % 45.23 ± 12.28 43.40 ± 12.60 47.06 ± 11.71 0.005
 Area stenosis, % 68.95 ± 14.60 66.79 ± 15.67 71.11 ± 13.13 0.006
 Reference vessel diameter, mm 2.69 ± 0.68 2.64 ± 0.62 2.73 ± 0.73 0.242
 Post-stent MLA, mm2 5.01 ± 1.96 5.16 ± 2.34 4.89 ± 1.57 0.334

OCT, optical coherence tomography; UHR, UA to HDL-C ratio; CAD, coronary artery disease; PCI, percutaneous coronary intervention; UA, uric acid; NSTEMI, non-ST segment elevated myocardial infarction; STEMI, ST segment elevated myocardial infarction; SD, standard deviation; WBC, white blood cell; Hb, hemoglobin; HbA1c, glycosylated hemoglobin; NT-proBNP, N-terminal B-type natriuretic peptide; Hs-cTnI, high-sensitivity cardiac troponin I; CK-MB, creatine kinase-MB; eGFR, estimated glomerular filtration rate; TC, total cholesterol; TG, total triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; Apo, apolipoprotein; Lp(a), lipoprotein (a); TSH, thyroid stimulating hormone; LVEF, left ventricular ejection fraction; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; TCFA, thin-cap fibroatheroma; FCT, fibrous cap thickness; MLA, minimal lumen area; MLD, minimal lumen diameter